GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rubius Therapeutics Inc (STU:5RT) » Definitions » Stock Based Compensation

Rubius Therapeutics (STU:5RT) Stock Based Compensation : €14.86 Mil (TTM As of Dec. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Rubius Therapeutics Stock Based Compensation?

Rubius Therapeutics's Stock Based Compensation for the three months ended in Dec. 2022 was €-1.25 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2022 was €14.86 Mil.


Rubius Therapeutics Stock Based Compensation Historical Data

The historical data trend for Rubius Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rubius Therapeutics Stock Based Compensation Chart

Rubius Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Stock Based Compensation
Get a 7-Day Free Trial 24.20 37.14 27.68 31.52 14.90

Rubius Therapeutics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.12 7.50 4.77 3.84 -1.25

Rubius Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.86 Mil.


Rubius Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Rubius Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Rubius Therapeutics (STU:5RT) Business Description

Traded in Other Exchanges
N/A
Address
124 Washington Street, Suite 101, Foxborough, MA, USA, 02035
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Rubius Therapeutics (STU:5RT) Headlines

No Headlines